Data field position,Column A,Column B,Column C,Column D,Column E,Column F,Column G,Column H,Column I,Column J,Column K,Column L,Column M,Column N,Column O,Column P,Column Q,Column R,Column S,Column T,Column U,Column V,Column W,Column X,Column Y,Column Z,Column AA,Column AB,Column AC,Column AD,Column AE,Column AF,Column AG,Column AH,Column AI,Column AJ,Column AK,Column AL,Column AM,Column AN,Column AO,Column AP,Column AQ,Column AR,Column AS,Column AT,Column AU,Column AV,Column AW,Column AX,Column AY,Column AZ,Column BA,Column BB,Column  BC,Column BD,Column BE,Column BF,Column BG,Column BH,Column BI,Column BJ,Column BK,Column BL,Column BM,Column BN,Column BO,Column BP,Column BQ,Column BR,Column BS,Column BT,Column BU,Column BV,Column BW,Column BX,Column BY,Column BZ,Column CA,Column CB,Column CC,Column CD,Column CE,Column CF,Column CG,Column CH,Column CI,Column CJ,Column CK,Column CL,Column CM,Column CN,Column CO,Column CP,Column CQ,Column CR ,Column CS,Column CT,Column CU,Column CV,Column CW,Column CX,Column CY
Data field,flscode,flsname,Data completeness (%),Total submitted,Total submitted (spine),Total submitted (hip),"Total submitted (non-hip, non-spine)",Percentage submitted (spine),Percentage submitted (hip),"Percentage submitted (non-hip, non-spine)",Total submitted (under 75),Total submitted (over 75),Estimated caseload,Percentage of estimated caseload submitted (all patients),Percentage of estimated caseload submitted (under 75),Percentage of estimated caseload submitted (over 75),Number assessed within 90 days (all patients),Percentage assessed within 90 days,Number DXA within 90 days (all patients),Percentage DXA within 90 days (all patients),Number receiving a falls assessment (all patients),Number receiving a falls assessment (under 75),Number receiving a falls assessment (over 75),Percentage receiving a falls assessment (all patients),Percentage receiving a falls assessment (under 75),Percentage receiving a falls assessment (over 75),Number of patients with a treatment recommendation (all patients)  ,Number of patients with a treatment recommendation (under 75),Number of patients with a treatment recommendation (over 75),Percentage of patients with a treatment recommendation (all patients),Percentage of patients with a treatment recommendation (under 75),Percentage of patients with a treatment recommendation (over 75),Oral bisphosphonates - %,Total number of patients receiving bisphosphonates,Zoledronate - %,Total number of patients receiving zoledronate,Denosumab - %,Total number of patients receiving denosumab,Raloxifene - %,Total number of patients receiving raloxifene,Teriparatide - %,Total number of patients receiving teriparatide,Romosozumab - %,Total number of patients receiving romosozumab,Referred to GP - %,Total number of patients referred to a GP,Clinical opinion %,Total number of patient referred for clinical opinion,Number of patients due follow up (non-hip fracture),Number of patients due follow up (non-hip fracture patients) (under 75),Number of patients due follow up (non-hip fracture patients) (over 75),Percentage of patients due follow up (non-hip fracture),Number of patients due follow up (all patients),Number of patients started strength and balance (non-hip fracture),Number of patients started strength and balance (non-hip fracture) (under 75),Number of patients started strength and balance (non-hip fracture) (over 75),Percentage of patients started strength and balance (non-hip fracture),Percentage of patients started strength and balance (non-hip fracture) (under 75),Percentage of patients started strength and balance (non-hip fracture) (over 75),Number of patients due follow up (Hip fracture patients),Number of patients followed up (all fractures),Number of patients followed up (hip fractures),Number of patients followed up (non-hip fractures),Percentage of patients followed up (all fractures),Percentage of patients followed up (hip fractures),Percentage of patients followed up (non-hip fractures),Number of patients commenced bone therapy by 1st follow up,Percentage of patients commenced bone therapy by 1st follow up,Total number of patients receiving oral bisphosphonates,oral bisphosphonates %,Total number of patients receiving zoledronate,zoledronate %,Total number of patients receiving denosumab,denosumab %,Total number of patients receiving raloxifene,raloxifene %,Total number of patients receiving teriparatide,Teriparatide %,Total number of patients receiving romosozumab,Romosozumab %,Total number of patients referred to GP,Referred to GP %,Total number of patients referred for clinical opinion,Referred for clinical opinion %,Number of patients due follow up at 1 year ,Number adherent to bone therapy at 12 months,Percentage adherent to bone therapy at 12 months,Total number of patients adherent to oral bisphosphonates,Oral bisphosphonates %,Total number of patients adherent to Zoledronate,Zoledronate %,Total number of patients receiving denosumab,Denosumab - %,Total number of patients receiving raloxifene,Raloxifene - %,Total number of patients receiving teriparatide,Teriparatide - %,Total number of patients receiving romosozumab,Romosozumab - %,Total number of patients referred to a GP,Referred to GP - %,Total number of patients referred for clinical opinion,Referred for clinical opinion %
Data field description,the 3 digit code used to identify each FLS,The name of the FLS submitting data,The percentage of fields with >80% complete data,The number of cases submitted,The number of spine fracutre patients submitted,The number of hip fracture patients submitted,The number of non-spine and non-hip fracutre patients submitted,The percentage of patients submitted with a spine fracture,The percentage of patients submitted with a hip fracture,The percentage of patients submitted with a non-hip and non-spine fracture ,The number of patients submitted aged <75,The number of patients submitted aged >75,The number of patients the FLS is estimated to see,The percentage of patients the FLS is estimated to see,The percentage of patients the FLS is estimated to see aged <75,Percentage of estimated caseload submitted (over 75),The percentage of patients the FLS is estimated to see aged >75,The number of patients assessed by an FLS within 90 days of diagnosis of a fragility fracture,The number of patients where a DXA scan was completed within 90 days of diagnosis of a fragility fracture,The percentage of patients where a DXA scan was completed within 90 days of diagnosis of a fragility fracture,The number of patients receiving a falls assessment,The number of patients receiving a falls assessment aged <75,The number of patients receiving a falls assessment aged >75,The percentage of patients receiving a falls assessment,The percentage of patients receiving a falls assessment aged <75,The percentage of patients receiving a falls assessment aged >75,The number of patients with a treatment recommendation,The number of patients with a treatment recommendation aged <75,The number of patients with a treatment recommendation aged >75,The percentage of patients with a treatment recommendation,The percentage of patients with a treatment recommendation aged <75,The percentage of patients with a treatment recommendation aged >75,The percentage of patients with oral bisphosphonates recommendation,Total number of patients receiving bisphosphonates recommendation,The percentage of patients with Zoledronate recommendation,Total number of patients receiving zoledronate recommendation,The percentage of patients with Denosumab recommendation,Total number of patients receiving denosumab recommendation,The percentage of patients with Raloxifene recommendation,Total number of patients receiving raloxifene recommendation,The percentage of patients with Teriparatide recommendation,Total number of patients receiving teriparatide recommendation,The percentage of patients with romosozumab recommendation,Total number of patients receiving romosozumab recommendation,The percentage of patients referred to a GP for bone therapy by each FLS,Total number of patients referred to a GP,The percentage of patients referred for clinical opinion for each FLS,Total number of patient referred for clinical opinion,The number of non-hip fracture patients due 12-16 week follow up (of those prescribed anti-osteoporosis medication or referred for further clinical opinion or to their GP),The number of non-hip fracture patients due 12-16 week follow up aged <75 (of those prescribed anti-osteoporosis medication or referred for further clinical opinion or to their GP),The number of non-hip fracture patients due 12-16 week follow up aged >75 (of those prescribed anti-osteoporosis medication or referred for further clinical opinion or to their GP),Percentage of patients due follow up (non-hip fracture),Number of patients due follow up (all patients),The number of non-hip fracture patients started strength and balance,The number of non-hip fracture patients started strength and balance aged <75,The number of non-hip fracture patients started strength and balance aged >75,The percentage of non-hip fracture patients started strength and balance,The percentage of non-hip fracture patients started strength and balance aged <75,The percentage of non-hip fracture patients started strength and balance aged >75,The number of hip fracture patients eligible to have 12–16 week monitoring contact (of those prescribed anti-osteoporosis medication or referred for further clinical opinion or to their GP),The number of patients followed up within 12-16 weeks after fracture diagnosis,The number of hip fracture patients followed up within 12-16 weeks after fracture diagnosis,The number of non-hip fracture patients followed up within 12-16 weeks after fracture diagnosis,The percentage of patients followed up within 12-16 weeks after fracture diagnosis,The percentage of hip fracture patients followed up within 12-16 weeks after fracture diagnosis,The percentage of non-hip fracture patients followed up within 12-16 weeks after fracture diagnosis,The number of patients who commenced anti-osteoporosis medication within 12-16 weeks of diagnosis of a fracture,The percentage of patients who commenced anti-osteoporosis medication within 12-16 weeks of diagnosis of a fracture,Total number of patients receiving oral bisphosphonates by 1st follow up,The percentage of patients receiving oral bisphosphonates following 1st follow up,Total number of patients receiving zoledronate following 1st follow up,The percentage of patients receiving oral zolendronate following 1st follow up,Total number of patients receiving denosumab following 1st follow up,The percentage of patients receiving oral denosumab following 1st follow up,Total number of patients receiving raloxifene following 1st follow up,The percentage of patients receiving raloxifene following 1st follow up,Total number of patients receiving teriparatide following 1st follow up,The percentage of patients receiving oral teriparatide following 1st follow up,Total number of patients receiving romosozumab following 1st follow up,The percentage of patients receiving romosozumab following 1st follow up,Total number of patients referred to GP following 1st follow up,The percentage of patients referred to GP following 1st follow up,Total number of patients referred for clinical opinion following 1st follow up,The percentage of patients referred for clinical opinion 1st follow up following 1st follow up,The number of patients eligible for monitoring at 12 months after their fracture following 1st follow up,The number of patients who are prescribed anti-osteoporosis medication (or referred for further clinical opinion or to their GP) for whom adherence was confirmed at 12 months after their fracture,The percentage of patients who are prescribed anti-osteoporosis medication (or referred for further clinical opinion or to their GP) for whom adherence was confirmed at 12 months after their fracture,Total number of patients adherent to oral bisphosphonates at 12 months,The percentage of patients adherent to oral bisphosphonates at 12 months,Total number of patients adherent to Zoledronate at 12 months,The percentage of patients adherent to zoledronate at 12 months,Total number of patients receiving denosumab at 12 months,The percentage of patients adherent to denosumab at 12 months,Total number of patients receiving raloxifene at 12 months,The percentage of patients adherent to raloxifene at 12 months,Total number of patients receiving teriparatide at 12 months,The percentage of patients adherent to teriparatide at 12 months,Total number of patients receiving romosozumab 12 months,The percentage of patients adherent to romosozumab at 12 months,Total number of patients referred to a GP at 12 months,The percentage of patients referred to GP at 12 months,Total number of patients referred for clinical opinion at 12 month,The percentage of patients referred for clinical opinion at 12 months
Data field type,String,String,Percentage,Integer,Integer,Integer,Integer,Percentage,Percentage,Percentage,Integer,Integer,Integer,Percentage,Percentage,Percentage,Percentage,Integer,Integer,Percentage,Integer,Integer,Integer,Percentage,Percentage,Percentage,Integer,Integer,Integer,Percentage,Percentage,Percentage,Percentage,Integer,Percentage,Integer,Percentage,Integer,Percentage,Integer,Percentage,Integer,Percentage,Integer,Percentage,Integer,Percentage,Integer,Integer,Integer,Integer,Percentage,Integer,Integer,Integer,Integer,Percentage,Percentage,Percentage,Integer,Integer,Integer,Integer,Percentage,Percentage,Percentage,Integer,Percentage,Integer,Percentage,Integer,Percentage,Integer,Percentage,Integer,Percentage,Integer,Percentage,Integer,Percentage,Integer,Percentage,Integer,Percentage,Integer,Integer,Percentage,Integer,Percentage,Integer,Percentage,Integer,Percentage,Integer,Percentage,Integer,Percentage,Integer,Percentage,Integer,Percentage,Integer,Percentage
Data field format,String,String,n.n,n   ,n  ,n,n,n.n,n.n,n.n,n,n,n,n.n,n.n,n.n,n.n,n,n,n.n,n,n,n,n.n,n.n,n.n,n,n,n,n.n,n.n,n.n,n.n,n,n.n,n,n.n,n,n.n,n,n.n,n,n.n,n,n.n,n,n.n,n,n,n,n,n.n,n,n,n,n,n.n,n.n,n.n,n,n,n,n,n.n,n.n,n.n,n,n.n,n,n.n,n,n.n,n,n.n,n,n.n,n,n.n,n,n.n,n,n.n,n,n.n,n,n,n.n,n,n.n,n,n.n,n,n.n,n,n.n,n,n.n,n,n.n,n,n.n,n,n.n